New triple combo aims to tackle Hard-to-Treat liver cancer
NCT ID NCT07537777
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow cancer growth and improve survival. Participants will receive treatment for up to 2 years, with close monitoring for side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Benmelstobart (an immunotherapy drug), Anlotinib (a targeted therapy drug), and SBRT (a precise type of radiation therapy)
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced liver cancer that has spread and stopped responding to initial therapy.
What could go wrong
This is a small, early-phase trial with only 29 participants and no comparison group, so results may not apply broadly. The combination of drugs and radiation may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••